

CBL Polyclonal Antibody

catalog number: E-AB-16288

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

| | |
|---------------------|--|
| Reactivity | Human;Mouse |
| Immunogen | Synthetic peptide of human CBL |
| Host | Rabbit |
| Isotype | IgG |
| Purification | Affinity purification |
| Conjugation | Unconjugated |
| buffer | Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol. |

Applications

Recommended Dilution

| | |
|-----------|--------------|
| WB | 1:500-1:2000 |
|-----------|--------------|

Data



Western Blot analysis of Raji and 231 cell using CBL

Polyclonal Antibody at dilution of 1:550

Calculated-MV:100 kDa

Preparation & Storage

| | |
|-----------------|--|
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended. |

Background

This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder

For Research Use Only